Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: Results of a first-in-man study

Cancer Chemotherapy and Pharmacology

Volumn 75, Issue 4, 2015, Pages 851-859

  Hurwitz, Herbert I ^a   Smith, David C ^b   Pitot, Henry C ^c   Brill, Jeffrey M ^d   Chugh, Rashmi ^b   Rouits, Elisabeth ^e   Rubin, Joseph ^c   Strickler, John ^a   Vuagniaux, Gregoire ^e   Sorensen, J Mel ^d   Zanna, Claudio ^e  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c MAYO CLINIC   (United States)

^d Ascenta Therapeutics   (United States)

^e DEBIOPHARM SA   (Switzerland)

Author keywords

Apoptosis; AT 406; Cancer; DEBIO1143; IAP; Resistance

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; CELLULAR INHIBITOR OF APOPTOSIS PROTEIN 1; DEBIO 1143; GAMMA GLUTAMYLTRANSFERASE; INHIBITOR OF APOPTOSIS PROTEIN 1; INTERLEUKIN 8; M30 PROTEIN; M65 PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; AZOCINE DERIVATIVE; BENZHYDRYL DERIVATIVE; CCL2 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; N-BENZHYDRYL-5-(2-(METHYLAMINO)PROPANAMIDO)-3-(3-METHYLBUTANOYL)-6-OXODECAHYDROPYRROLO(1,2-A)(1,5)DIAZOCINE-8-CARBOXAMIDE;

ABDOMINAL PAIN; ADRENAL CANCER; ADULT; ADVANCED CANCER; AFRICAN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMERICAN INDIAN; ANGIOSARCOMA; ANTINEOPLASTIC ACTIVITY; APPENDIX CANCER; AREA UNDER THE CURVE; ARTICLE; ASIAN; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CAUCASIAN; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; COHORT ANALYSIS; COLORECTAL CANCER; CONSTIPATION; CRANIAL NEUROPATHY; DIGESTIVE SYSTEM CANCER; DISEASE SEVERITY; DOSE LIMITING TOXICITY; DRUG ABSORPTION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FIRST IN HUMAN STUDY; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEMANGIOPERICYTOMA; HUMAN; HUMAN TISSUE; INTESTINE OBSTRUCTION; LIMIT OF DETECTION; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MELANOMA; METASTASIS; MIDDLE AGED; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; MYOEPITHELIOMA; NAUSEA; NON SMALL CELL LUNG CANCER; ONCOCYTOMA; OVARY CANCER; PENIS CARCINOMA; PENIS SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SALIVARY GLAND CANCER; SOLID TUMOR; TIME TO MAXIMUM PLASMA CONCENTRATION; TOXICITY TESTING; TOXICOLOGICAL PARAMETERS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; URINE RETENTION; VOMITING; APOPTOSIS; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECTS; MULTICENTER STUDY; NEOPLASMS; ORAL DRUG ADMINISTRATION; PATHOLOGY;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; AZOCINES; BENZHYDRYL COMPOUNDS; CHEMOKINE CCL2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MAXIMUM TOLERATED DOSE; NEOPLASMS; TREATMENT OUTCOME;

EID: 84925535476     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-015-2709-8     Document Type: Article

References (19)

1. Zhang T, Li Y, Zou P, Yu JY, McEachern D, Wang S, Sun D (2013) Physiologically based pharmacokinetic and pharmacodynamic modeling of an antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in a mouse xenograft model of human breast cancer. Biopharm Drug Dispos 34(6):348-359. doi: 10.1002/bdd.1850
2. Miura K, Fujibuchi W, Ishida K, Naitoh T, Ogawa H, Ando T, Yazaki N, Watanabe K, Haneda S, Shibata C, Sasaki I (2011) Inhibitor of apoptosis protein family as diagnostic markers and therapeutic targets of colorectal cancer. Surg Today 41(2):175-182. doi: 10.1007/s00595-010-4390-1
3. Dubrez L, Berthelet J, Glorian V (2013) IAP proteins as targets for drug development in oncology. OncoTargets Ther 9:1285-1304. doi: 10.2147/ott.s33375
4. Brunckhorst MK, Lerner D, Wang S, Yu Q (2012) AT-406, an orally active antagonist of multiple inhibitor of apoptosis proteins, inhibits progression of human ovarian cancer. Cancer Biol Ther 13(9):804-811. doi: 10.4161/cbt.20563
5. Fulda S (2007) Inhibitor of apoptosis proteins as targets for anticancer therapy. Expert Rev Anticancer Ther 7(9):1255-1264. doi: 10.1586/14737140.7.9.1255
6. Fulda S (2013) Molecular pathways: targeting inhibitor of apoptosis proteins in cancer - from molecular mechanism to therapeutic application. Clin Cancer Res. doi: 10.1158/1078-0432.ccr-13-0227
7. Cai Q, Sun H, Peng Y, Lu J, Nikolovska-Coleska Z, McEachern D, Liu L, Qiu S, Yang CY, Miller R, Yi H, Zhang T, Sun D, Kang S, Guo M, Leopold L, Yang D, Wang S (2011) A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. J Med Chem 54(8):2714-2726. doi: 10.1021/jm101505d
8. Viert D, Rigotti S, Kadi L, Zanna C, Vuagniaux G, Matzinger O, Vozenin MC, Bourhis J (2014) Debio 1143, an oral antagonist of the inhibitor of apoptosis proteins (IAPs) sensitises multiple SCCHN models to radiotherapy. In: Paper presented at the European congress on head and neck oncology (ECHNO), Liverpool, UK, pp 24-26
9. Wong H, Budha NR, West K, Blackwood E, Ware JA, Yu R, Darbonne WC, Gould SE, Steigerwalt R, Erickson R, Hop CE, LoRusso P, Eckhardt SG, Wagner A, Chan IT, Mamounas M, Flygare JA, Fairbrother WJ (2012) Dogs are more sensitive to antagonists of inhibitor of apoptosis proteins than rats and humans: a translational toxicokinetic/toxicodynamic analysis. Toxicol Sci 130(1):205-213. doi: 10.1093/toxsci/kfs235
10. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228-247. doi: 10.1016/j.ejca.2008.10.026
11. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V, International Harmonization Project on L (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579-586. doi: 10.1200/JCO.2006.09.2403
12. Sikic BI, Eckhardt SG, Gallant G, Burris HA, Camidge DR, Colevas AD, Jones SF, Messersmith WA, Wakelee HA, Li H, Kaminker PG, Morris S, Infante JR (2011) Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of HGS1029, an inhibitor of apoptosis protein (IAP) inhibitor, in patients (Pts) with advanced solid tumors: results of a phase I study. J Clin Oncol 29 (suppl;):abstr 3008
13. Tolcher AW, Papadopoulos KP, Patnaik A, Fairbrother WJ, Wong H, Budha NR, Darbonne WC, Peale FV, Mamounas MJ, Royer-Joo S, Yu R, Portera CC, Bendell JC, Burris HA, Infante JR (2013) Phase I study of safety and pharmacokinetics (PK) of GDC-0917, an antagonist of inhibitor of apoptosis (IAP) proteins in patients (Pts) with refractory solid tumors or lymphoma. J Clin Oncol 31(suppl):abstr 2503
14. Amaravadi RK, Schilder RJ, Dy GK, Ma WW, Fetterly GJ, Weng DE, Graham MA, Burns JM, Chunduru SK, Condon SM, McKinlay MA, Adjei AA (2011) Phase 1 study of the smac mimetic TL32711 in adult subjects with advanced solid tumors and lymphoma to evaluate safety, pharmacokinetics, pharmacodynamics, and antitumor activity. Cancer Res 71(8(suppl 1)):LB-406. doi: 10.1158/1538-7445.AM2011-LB-406
15. Amaravadi RK, Senzer NN, Martin LP, Schilder RJ, LoRusso P, Papadopoulos KP, Weng DE, Graham M, Adjei AA (2013) A phase I study of birinapant (TL32711) combined with multiple chemotherapies evaluating tolerability and clinical activity for solid tumor patients. J Clin Oncol 31(suppl):abstr 2504
16. Erickson RI, Tarrant J, Cain G, Lewin-Koh SC, Dybdal N, Wong H, Blackwood E, West K, Steigerwalt R, Mamounas M, Flygare JA, Amemiya K, Dambach D, Fairbrother WJ, Diaz D (2013) Toxicity profile of small-molecule IAP antagonist GDC-0152 is linked to TNF-alpha pharmacology. Toxicol Sci 131(1):247-258. doi: 10.1093/toxsci/kfs265
17. Akazawa Y, Guicciardi ME, Cazanave SC, Bronk SF, Werneburg NW, Kakisaka K, Nakao K, Gores GJ (2013) Degradation of cIAPs contributes to hepatocyte lipoapoptosis. Am J Physiol Gastrointest Liver Physiol 305(9):G611-G619. doi: 10.1152/ajpgi.00111.2013
18. Deshmane SL, Kremlev S, Amini S, Sawaya BE (2009) Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interf Cytokine Res 29(6):313-326. doi: 10.1089/jir.2008.0027
19. Linder S, Olofsson MH, Herrmann R, Ulukaya E (2010) Utilization of cytokeratin-based biomarkers for pharmacodynamic studies. Expert Rev Mol Diagn 10(3):353-359. doi: 10.1586/erm.10.14